SEC Form 4 · accession 0001209191-16-118169
ReShape Lifesciences Inc. · RSLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lori Courtney McDougal
Director
Period of report
May 4, 2016
Accepted (ET)
May 6, 2016 · 5:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001371217
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Option (Right to Buy)F3 | $0.75 | May 4, 2016 | A | 3,000 | A | May 4, 2016 | May 4, 2026 | Common Stock | 3,000 | 3,000 | D |
| Director Option (Right to Buy)F1,F2 | $4.65 | holding | — | — | — | — | Jul 31, 2025 | Common Stock | 1,666 | 1,666 | D |
Explanation of responses
- F1On January 6, 2016, EnteroMedics Inc. effected a 1-for-15 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person. all previously reported exercise prices, option grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split.
- F225% of the shares subject to the option are exercisable immediately. The remaining 75% of the shares subject to the option shall vest in a series of thirty-six (36) successive equal monthly installments upon completion of each month beginning on August 31, 2015 and ending on July 31, 2018.
- F3Vests immediately as to 25% on date noted and thereafter in cumulative installments of 1/36th per month.
Remarks
THIS FILING REFLECTS THE POST SPLIT NUMBERS OF ALL SHARES, OPTIONS AND SIMILAR INSTRUMENTS HELD BY THE REPORTING PERSON AS PREVIOUSLY REPORTED.